Fei Dan, Zhang Xiaona, Liu Jinxiang, Tan Long, Xing Jie, Zhao Dongxu, Zhang Yang
Department of Ultrasonographic, China-Japan Union Hospital of Jilin University, Changchun, China.
Department of Anesthesiology, the First Hospital of Jilin University, Changchun, China.
Cell Physiol Biochem. 2018;51(3):1364-1375. doi: 10.1159/000495554. Epub 2018 Nov 27.
BACKGROUND/AIMS: Novel long non-coding RNA Fer-1-like protein 4 (FER1L4) has been reported to play crucial regulatory roles in tumor progression. However, its clinical significance and biological role in osteosarcoma (OS) is completely unknown. The aim of the present study was to investigate the role of FER1L4 in OS progression and the underlying mechanism.
We analyzed the expression levels of FER1L4 in tissues of OS patients and cell lines via quantitative RT-PCR (qRT-PCR). The effect of FER1L4 on cell proliferation, colony formation, migration and invasion was analyzed by cell counting kit-8 (CCK-8), colony formation, wound healing and transwell invasion assay, respectively. Novel targets of FER1L4 were selected through a bioinformatics soft and confirmed using a dual-luciferase reporter system and qRT-PCR. To detect the role of FER1L4 in vivo tumorigenesis, tumor xenografts were created.
We found that the expression of FER1L4 was significantly downregulated in OS tissues and cell lines; moreover, low expression of FER1L4 was associated with advanced tumor-nude-metastasis (TNM) stage, lymph node metastases, and poor overall survival. Functional assays showed that upregulation of FER1L4 significantly inhibited OS cell proliferation, colony formation, migration, and invasion in vitro, as well as suppressed tumor growth in vivo. Assays performed to determine the underlying mechanism, indicated that FER1L4 interacted directly with miR-18a-5p. Subsequently, we found that FER1L4 significantly increased PTEN expression, a known target of miR-18a-5p, in OS cells. Furthermore, PTEN was found to be down-regulated, and positively correlated with FER1L4 in OS tissues.
These findings suggest that FER1L4, acting as a competing endogenous RNA (ceRNA) of miR-18a-5p, exerts its anti-cancer role by modulating the expression of PTEN. Thus, FER1L4 may be a novel target for the prevention and treatment of OS.
背景/目的:据报道,新型长链非编码RNA铁蛋白1样蛋白4(FER1L4)在肿瘤进展中发挥关键调节作用。然而,其在骨肉瘤(OS)中的临床意义和生物学作用尚完全未知。本研究旨在探讨FER1L4在OS进展中的作用及其潜在机制。
我们通过定量逆转录聚合酶链反应(qRT-PCR)分析了FER1L4在OS患者组织和细胞系中的表达水平。分别采用细胞计数试剂盒-8(CCK-8)、集落形成、伤口愈合和Transwell侵袭实验分析FER1L4对细胞增殖、集落形成、迁移和侵袭的影响。通过生物信息学软件筛选FER1L4的新靶点,并使用双荧光素酶报告系统和qRT-PCR进行验证。为检测FER1L4在体内肿瘤发生中的作用,构建了肿瘤异种移植模型。
我们发现FER1L4在OS组织和细胞系中的表达显著下调;此外,FER1L4低表达与晚期肿瘤-淋巴结转移(TNM)分期、淋巴结转移及总体生存率低相关。功能实验表明,上调FER1L4可显著抑制OS细胞的体外增殖、集落形成、迁移和侵袭,并在体内抑制肿瘤生长。为确定潜在机制所进行的实验表明,FER1L4直接与miR-18a-5p相互作用。随后,我们发现FER1L4可显著增加OS细胞中miR-18a-5p的已知靶点PTEN的表达。此外,在OS组织中发现PTEN表达下调,且与FER1L4呈正相关。
这些发现表明,FER1L4作为miR-18a-5p的竞争性内源性RNA(ceRNA),通过调节PTEN的表达发挥其抗癌作用。因此,FER1L4可能是预防和治疗OS的新靶点。